Salmedix

About:

It focuses on the treatment of hematologic malignancies or blood cancers.

Top Investors: H.I.G. Capital, OrbiMed, Novo Holdings, Alexandria Real Estate Equities, Versant Ventures

Description:

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Total Funding Amount:

$72.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2000-11-01

Founders:

David Kabakoff

Number of Employees:

11-50

Last Funding Date:

2005-10-19

IPO Status:

Private

Industries: